Abstract: An enhanced activity aqueous disinfecting solution having a pH of from about 0.5 to about 6 and consisting essentially of (i) hydrogen peroxide in a concentration of from about 0.
Abstract: The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).
Abstract: A medicament for preventive and/or therapeutic treatment of an ocular disease resulting from vascular hyperpermeability, for example diabetic retinopathy or age-related macular degeneration, which comprises as an active ingredient a retinoid such as all trans retinoic acid or 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.
Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
Type:
Grant
Filed:
June 23, 2008
Date of Patent:
October 6, 2009
Assignee:
Janssen Pharmaceutica N. V.
Inventors:
Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan DeAngelis, Keith Demarest, Patricia Pelton
Abstract: An object of the present invention is to find a new pharmaceutical application of a prostaglandin F2? derivative. It was found that the prostaglandin F2? derivative inhibits glutamate-induced retinal neuronal cell death in a concentration-dependent manner in rat fetal retinal neuronal cells, in other words, the prostaglandin F2? derivative acts directly on the retinal neuronal cells and exhibits a protective effect. Accordingly, the prostaglandin F2? derivative is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage.
Abstract: The present invention provides a method for treating or reducing damage to the optic nerve in a subject comprising administering to the subject a therapeutically effective amount of prostaglandin J2 alone or in combination with an effective amount of GM-CSF. In particular aspects of the invention, the subject is a mammal, and in further aspects the mammal is a human.
Abstract: The invention relates to a method for inhibiting the biological acidification of water which is in contact with materials containing sulfur in reduced form or with elemental sulfur, susceptible to oxidation on the part of Thiobacilli, comprising putting said materials in contact with soluble inorganic salts at concentrations ranging from 0.4 normal to saturation.
Type:
Grant
Filed:
April 26, 2004
Date of Patent:
September 8, 2009
Assignees:
ENI S.p.A., Enitecnologie S.p.A.
Inventors:
Francesco Crescenzi, Antonella Crisari, Cesare Achille Piatti
Abstract: Compounds and compositions the same. Method of making the compounds. The compounds and/or compositions used as an analgesic, anaesthetic, antifoulant, aversant, irritant, sternutator, neurodegenerator, counter irritant (delayed), rubifaciant, stomachic, fungicide, insecticide, preservative, circulatory stimulant, cardio-protective agent, immune booster, decongestant, anti-inflammatory agent, incapacitant, biocide, mildewcide, pharmaceutical, repellent, flavorant, carminative, antismoking agent, and/or antithrombotic agent. One of the compounds being lidocaine nonivamide. The compositions comprising one or more of: the compounds, one or more of an antioxidant, a UV absorber, and one or more biocides such as, for example, OBPA.
Abstract: A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the patient to cause healing, accelerated healing or prevention of the wound, ulcer or inflammation. Additional active ingredients may include a promoter of mitochondrial function or an antioxidant.
Type:
Application
Filed:
January 22, 2009
Publication date:
August 27, 2009
Applicant:
BIOCHEMICS, INC.
Inventors:
Stephen G. Carter, Zhen Zhu, Kanu Patel, Diane L. Kozwich
Abstract: The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
Abstract: The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors, comprising administering multiple therapeutic compounds like DFMO, SAM486A, a verinoid and a cytotoxic drug and placing the patient on a low polyamine diet and/or providing the patient with a polyamine limiting dietary supplement.
Abstract: A method and process for producing youthful appearing, small-pored, and smooth skin by pre-treating the skin topically with retinoic acid, applying carbon particles on the skin, removing the carbon particles by exploding them with laser light, and post-treating the skin topically with retinoic acid. When treating the face, removing the carbon particles requires only about 4 minutes. The laser light itself does not injure the skin. Treatment by explosion of the carbon particles stimulates the production of collagen in the high dermis leaving the epidermis intact, with no removal of stratum corneum. Repeated intermittent treatments of exploding carbon particles and topical application of retinoic acid to the skin produce the desired results in the skin indefinitely as long as the treatment and applications are continued.
Abstract: The present invention provides the use of all-trans retinoic acid for the production of a pharmaceutical composition for the treatment of acute myeloid leukemia, which use is characterized in that the patients are selected from the group of non-M3 acute myeloid leukemia patients according to a physiologic concentration, e.g. a level of MN1 below a certain critical level analysed in total blood cells, preferably analysed in bone marrow cells. The critical level of MN1 can be determined according to known methods, e.g. by specific determination of the presence of MN1, e.g. using specific anti-MN1 antibody, e.g. in an ELISA or in another immuno specific assay. Preferably, the level of MN1 is determined at its transcription level, e.g. as the concentration of mRNA encoding MN1.
Type:
Application
Filed:
March 26, 2007
Publication date:
August 6, 2009
Inventors:
Michael Heuser, Arnold Ganser, Konstanze Dohner, Richard Schlenk
Abstract: Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.
Abstract: This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16, wherein the pharmaceutically active substance exhibits an improved stability. In particular, a composition is provided that comprises cetalkonium chloride micelles incorporating the prostaglanding-like therapeutic agent, latanoprost. This invention also relates to ophthalmic compositions containing such micellar compositions and methods of using these ophthalmic compositions for the treatment of eye conditions.
Abstract: The novel antimicrobial composition is disclosed including from about 60 to 95% of a lipophilic polar solvent such as propylene glycol, ethylene glycol, or isopropanol and from about 0.5 to 5% of a mixture of C8 to C14 fatty acids. Other constituents of the present invention may include water, an alcohol (such as ethanol or propanol) or a mixture thereof. Also disclosed is a novel method of killing harmful microbes on the udder of a milk-producing animal using the above-mentioned composition.
Abstract: A skin treatment composition or cosmetic product comprising a) two or more active components, namely, at least one dermatological acid and at least one meroterpene and b) a dermatologically acceptable carrier.
Abstract: This invention provides sarganol bis-succinate and alkyl and aryl derivatives thereof as potent apoptogens (antineoplastic agents) with high selectivity for cancer cells.
Abstract: A method of producing a retinyl ester compound comprising subjecting a composition comprising retinyl or a retinyl ester and a fat or oil of animal or vegetable origins to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester.
Type:
Application
Filed:
November 6, 2008
Publication date:
May 14, 2009
Applicant:
CONOPCO, INC., D/B/A UNILEVER
Inventors:
John Anthony BOSLEY, Clive Roderick HARDING, Christopher RAWLINS, Julia Sarah ROGERS, Ian Richard SCOTT
Abstract: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
Type:
Application
Filed:
November 14, 2008
Publication date:
May 14, 2009
Applicant:
CAYMAN CHEMICAL COMPANY
Inventors:
Nancy S. Barta, Gregory W. Endres, Andrei M. Kornilov, Kirk M. Maxey, Adam Uzieblo
Abstract: Particles are provided for use in restorative procedures to treat and/or retard alopecia The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in various colors or with customized coloration to match desired scalp colors. Moreover, such particles may be loaded to provide localized treatment with an active component agent directed at restoration of normal function and hair production within the hair follicle.
Type:
Application
Filed:
October 30, 2007
Publication date:
April 30, 2009
Applicant:
CELONOVA BIOSCIENCES, INC.
Inventors:
Olaf Fritz, Ulf Fritz, Ronald Wojcik, Ralph E. Gaskins, JR.
Abstract: In an aqueous composition comprising a 15-keto-prostaglandin compound as an active ingredient, a polyoxyethylene castor oil derivative is admixed. By admixing a polyoxyethylene castor oil derivative, the solubility of the 15-keto-PG compound in water is increased. In a preferable embodiment, the aqueous composition may further comprise a quaternary ammonium type cationic surface active agent as a preservative. The composition of this embodiment exhibits high antimicrobial preservative effectiveness against indigenous bacterium in the eyes such as Staphylococcus aureus and therefore, the composition is especially useful as ophthalmic composition for ocular topical administration.
Abstract: This invention is directed to a crystalline acid of a lipoxin A4 analog of Formula (II): wherein: R1 is —O—, —S(O)t— (where t is 0, 1 or 2), or a straight or branched alkylene chain; and R2 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from f alkyl, alkoxy, halo, haloalkyl and haloalkoxy); and wherein the compound of Formula (II) is a single stereoisomer or any mixture of stereoisomers. This crystalline acid is useful in treating disease-states characterized by inflammation, such as inflammatory and autoimmune disorders or pulmonary or respiratory tract inflammations in humans. Methods of preparing the crystalline acid are also described.
Abstract: Provided is a method for treating a condition or disease which is one of the indications for opioid use, which comprises administering a combination of: (a) a pharmaceutically effective amount of an opioid, and (b) a pharmaceutically effective amount of a prostaglandin (PG) compound represented by the formula (I): to a patient in need thereof.
Abstract: The present invention relates to a method of translation or inflammatory response blockade by using a compound that binds to eIF4A, which is the 264th amino acid residue, a method of developing an anti-inflammation, anti-cancer or anti-viral agent by screening a compound that binds to eIF4A.
Abstract: Provided is a method for treating a condition or disease which is one of the indications for NSAID use, which comprises administering a combination of: (a) a pharmaceutically effective amount of a NSAID, and (b) a pharmaceutically effective amount of a prostaglandin (PG) compound represented by the formula (I): to a subject in need thereof.
Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.
Type:
Application
Filed:
February 13, 2007
Publication date:
December 25, 2008
Inventors:
Daniel Raederstorff, Joseph Schwager, Goede Schueler
Abstract: The present invention aims to provide a novel agent for treating and/or preventing diabetes which agent can not only control a blood sugar level but also fundamentally treat a patient with type I diabetes suffering from destruction of ? cells and a patient with type II diabetes suffering from dysfunction in insulin secretion. The present invention provides an agent for treating and/or preventing diabetes, the agent containing retinoic acid as an active ingredient. Retinoic acid incorporated as an active ingredient may be all-trans retinoic acid, an isomer thereof, a derivative thereof, a salt thereof or a prodrug thereof. Retinoic acid may be incorporated singly. Alternatively, composite particles of retinoic acid and an appropriate inorganic or organic substance are prepared, and the retinoic acid composite particles may be incorporated.
Abstract: This invention relates to compositions and processes for stimulating the growth of mammalian hair comprising the topical application of compositions comprising a hair growth stimulating and/or hair loss prevention agent, and a hair and/or skin lightening and/or neutralization agent, in association with a topical pharmaceutical carrier. Unlike other products, the composition of the invention can be used with dyed/treated hair so as to not affect the color of the hair.
Type:
Application
Filed:
June 12, 2008
Publication date:
November 6, 2008
Inventors:
Mari M. Shaw, Marc S. Cohen, Nancy G. Swartz
Abstract: An emulsion composition includes prostaglandin E1 (PGE1), a phospholipid with a high purity and a non-proton-providing surfactant that improves stability of PGE1. Embodiments of the emulsion composition include an effective amount of PGE1, about 1% to about 30% (w/w) of a pharmaceutically acceptable oil as an oil base based on the weight of the emulsion composition, about 1% to about 30% (w/w) of a phospholipid with a high purity based on the weight of the oil base, about 1.6% to about 40% (w/w) of a non-proton-providing surfactant based on the weight of the oil base, and the balance of the emulsion composition being water.
Type:
Application
Filed:
August 15, 2007
Publication date:
September 25, 2008
Applicants:
TAIWAN LIPOSOME COMPANY (A TAIWAN CORPORATION), TLC Biopharmaceuticals, Inc. ( a United States business entity)
Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
Type:
Grant
Filed:
September 14, 2005
Date of Patent:
September 16, 2008
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan DeAngelis, Keith Demarest, Patricia Pelton
Abstract: This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.
Type:
Application
Filed:
October 31, 2007
Publication date:
September 4, 2008
Applicant:
Oregon Health and Sciences University
Inventors:
Jean-Baptiste Roullet, David A. McCarron
Abstract: Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. The BPI inducing agents include, for example, lipoxin compounds.
Abstract: Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
Type:
Grant
Filed:
April 11, 2005
Date of Patent:
August 26, 2008
Assignee:
MHR Institutional Partners IIA LP
Inventors:
Andrea Leone-Bay, Sam J. Milstein, Donald J. Sarubbi, Harry Leipold
Abstract: This invention is directed to a crystalline acid of a lipoxin A4 analog of Formula (II): wherein: R1 is —O—, —S(O)t— (where t is 0, 1 or 2), or a straight or branched alkylene chain; and R2 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from f alkyl, alkoxy, halo, haloalkyl and haloalkoxy); and wherein the compound of Formula (II) is a single stereoisomer or any mixture of stereoisomers. This crystalline acid is useful in treating disease-states characterized by inflammation, such as inflammatory and autoimmune disorders or pulmonary or respiratory tract inflammations in humans. Methods of preparing the crystalline acid are also described.
Abstract: Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty 5 acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.
Abstract: Cyanophenoxy carboxylic acid compounds and compositions for the delivery of active agents are provided. Methods of administration, treatment of disease and preparation are provided as well.
Type:
Grant
Filed:
August 4, 2006
Date of Patent:
June 24, 2008
Assignee:
Emisphere Technologies, Inc.
Inventors:
Destardi Moye-Sherman, David Gschneidner
Abstract: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit.
Abstract: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2? in a preparation containing prostaglandin F2?. The object was attained by formulating a prostaglandin F2? derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.
Abstract: Embodiments of the present invention include compositions and pharmaceutical compositions comprising citrulline and Hmg-CoA reductase inhibitors. Further embodiments relate to the use of such composition treat subjects and stimulating nitric oxide synthase.
Abstract: Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.
Type:
Application
Filed:
August 28, 2007
Publication date:
May 29, 2008
Inventors:
Donald Massaro, Gloria DeCarlo Massaro, Roshantha A. Chandraratna
Abstract: The subject invention provides a composition comprising a mixture of polypeptides in the form of a tannate salt wherein each polypeptide is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine and L-Lysine, methods of preparation and uses thereof.
Abstract: The present invention is directed to the use of lipoxin A4 analogs as therapeutic agents in the treatment and/or prevention of intestinal fibrosis.
Abstract: The invention relates to new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.
Type:
Grant
Filed:
March 11, 2007
Date of Patent:
May 13, 2008
Assignee:
Sami Labs Limited
Inventors:
Muhammed Majeed, Kalyanam Nagebhuananam, Rajendran Ramanujam, Subbalakshmi Prakash
Abstract: One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.